medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2013, Number 607

<< Back Next >>

Rev Med Cos Cen 2013; 70 (607)

VPH y cancer de cervix

Durán SO

Language: Spanish
References: 13
Page: 417-421
PDF size: 208.57 Kb.


ABSTRACT

Cervical carcinoma is of great relevance for public health. It is the third malignancy that affects women. It is estimated that around 490000 women are diagnosed with cervical cancer per year and of those diagnosed, 270000 will die from it. Molecular studies have demonstrated Human Papilloma Virus’ DNA to be present in most of the cervical cancers. HPV is an asymptomatic sexually transmitted disease generally acquired little after sexual activity debut. There are several types of HPV. HPV 16 and 18 are among the most important types since they cause about half and 13% of cervical carcinomas respectively. From these observations it has been concluded that is important to have good screening tests as well as the necessity to develop vaccines to avoid clinical manifestation.


REFERENCES

  1. Bedoya A, Jaramillo R, Baena A, et al. Location and density of immune cells in precursor lesions and cervical cancer. Cancer Microenvironment 2013; 6:69- 77.

  2. Chan W, Aguilar L, Soley C. Estado actual de la vacuna recombinante contra el virus del papiloma humano. AMC; 2008;4:203-209.

  3. Deodhar K. Screening for cervical cancer and Human Papilloma Virus: Indian context. Clin Lab Med 2012; 32:193-205.

  4. Diaz Maria. Human Papilloma Virus – prevention and tratment. Obstet Gynecol Clin N Am; 2008; 35:199-217.

  5. Einstein M, Schiller J, Viscidi R et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancer Infect Dis 2009;9:347-356.

  6. Glavão E, Soares D, Nunes C, et al. Knowledge about HPV and screening of cervical cancer among women from the metropollitan región of Natal, Brazil. ISRN Obstetrics and Gynecology 2013; ID930479 en http://dx.doi. org/10.1155/2013/930479.

  7. Kahn Jessica. HPV vaccination for the prevention of cervical intraepithelial neoplasia. The New England Journal of Medicine 2009;361:271-8.

  8. Katki H, Kinney W, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a populatoin-based study in routine clinical practice. Lancet Oncology 2011; 12:663-672.

  9. La Torre G, Waure C, Chiaradia G, et al. HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis. Vaccine 2007; 25:8352-8358.

  10. Leval A, Herweijer E, Ploner A, et al. Quadrivalent Human Papillomavirus Vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst;2013;105:469-474.

  11. Roland KB, Soman A, Bernard VB, Saraiya M. Human papillomavirus and papanicolau tests screening interval recommendations in the United States. American Journal of Obstetrics and Gynecology 2011; 205:447. e1-8.

  12. Rosi L, Dornelles D, da Rosa M et al. Efficacy of Human Papillomavirus Vaccines: A systematic quantitative review. International Journal of Gynecology and Cancer 2009;19: 1166- 1176.

  13. Trimble C, Frazer I. Development of therapeutic HPV vaccines. Lancet Oncology 2009; 10:975-80.




2020     |     www.medigraphic.com